CCRC® Preparation Guide: Coordinator Decisions in Clinical Research Study Guide

Apply it

A participant stops assigned treatment but agrees to scheduled assessments. The protocol evaluates outcomes regardless of treatment discontinuation. Continue those assessments with consent and document discontinuation details so the analysis can address the specified treatment effect.

Apply it

A screening test falls outside the protocol’s permitted assessment window, although its result is normal. Arrange an assessment within the required window and obtain investigator confirmation of eligibility before proceeding with enrollment or treatment assignment.

Apply it

A recruiter asks the dispensing team which treatment comes next before deciding whether to enroll a candidate. Protect the allocation sequence and complete eligibility and enrollment procedures without disclosing the upcoming assignment to the recruiter.

Apply it

A participant receives rescue therapy shortly before the second crossover period. Record the therapy and timing, notify the investigator, and follow protocol instructions about assessments and period eligibility because residual effects may affect the next comparison.

Apply it

A site must enroll 24 participants and expects 40% of screened candidates to fail eligibility. With a 60% enrollment yield and no other losses assumed, it should plan to screen approximately 40 candidates.

Apply it

A candidate signs immediately but says randomization guarantees the better treatment. Pause enrollment, explain chance assignment and uncertain benefit in accessible language, invite questions, and confirm understanding before proceeding with any study-specific screening procedure.

Apply it

An approved update adds a newly recognized risk and an extra assessment. Contact affected participants, explain both changes, arrange renewed consent as required, and document decisions before the additional research activity unless an immediate safety exception applies.

Apply it

An adolescent in a nontherapeutic study repeatedly refuses a research-only blood draw despite parental permission. Declining participation will not jeopardize the adolescent’s welfare. Keep the procedure paused, respect the refusal, explore concerns without pressure, document the discussion and involve the investigator. This vignette meets neither the serious-or-life-threatening therapeutic-study condition nor the welfare-jeopardy condition. The conclusion follows from the study’s purpose and the consequences of nonparticipation, rather than from the blood draw’s research-only label.

Apply it

A participant reports intense nausea managed at home without other serious features. Another has modest symptoms but requires unplanned inpatient hospitalization. Assess intensity separately from seriousness; the hospitalization is a key cue for serious-event evaluation.

Apply it

A participant develops a serious reaction resembling an effect listed as mild in the reference safety information. Preserve details of the actual severity and outcome so expectedness can be assessed against the described reaction, alongside causality.

Apply it

A participant’s relative reports an overnight hospitalization, but discharge records are unavailable. Notify the investigator immediately, support initial sponsor reporting with known facts, document missing information, and actively obtain records for follow-up assessment and reporting.

Apply it

An emergency physician states that knowing the assigned intervention will change immediate treatment. Contact the investigator and use the authorized emergency code-break process without delaying necessary care, then document disclosure and complete required notifications afterward.

Apply it

During a procedure, a participant develops an acute safety problem requiring the investigator to stop protocol-required testing. Support clinical care, document the reason for the departure, and coordinate required sponsor and ethics committee communications promptly.

Apply it

A clinic proposes publicly tagging patients in social-media recruitment posts. Replace this approach with an approved privacy-preserving contact method and neutral study information, while providing a private way to ask questions without pressure to enroll.

Apply it

A participant wants to stop the study product because travel is difficult but remains willing to answer scheduled outcome calls. Clarify and document that choice, involve the investigator in safety planning, and preserve permitted follow-up.

Apply it

A recruiter receives a personal enrollment bonus and pressures a hesitant candidate to sign immediately. Report the concern through the appropriate oversight process and restore a voluntary discussion with adequate time and balanced information before enrollment.

Apply it

A protocol collects frequent blood samples to characterize exposure after initial doses. Explain that these assessments address pharmacokinetic objectives, and verify the precise schedule rather than assuming every early study primarily measures definitive clinical benefit.

Apply it

A five-member committee includes four clinicians and a community member whose primary interest is outside medical sciences and who is independent of the institution/site. This meets the recommended numerical and membership categories, although collective expertise and applicable requirements still need assessment. If one clinician is the trial investigator, that clinician cannot vote or provide the committee’s opinion on the trial.

Apply it

An approved amendment changes visit windows and adds participant information. Confirm required approvals, train staff, update calendars and systems, and arrange the necessary consent discussion before applying the new procedures to affected participants at the site.

Apply it

A study finishes without a statistically convincing benefit, and the team proposes abandoning dissemination. Escalate the ethical reporting obligation and support accurate status and results information, including negative or inconclusive findings through the responsible study processes.

Apply it

An independent sponsor quality team requests records separately from the routine monitor. Recognize the audit function, identify the authorized scope, arrange secure access, and document findings and responses without altering original records to improve their appearance.

Apply it

Several visit records describe assessments when appointment logs show participants were absent. Preserve the records and relevant audit information, promptly raise the discrepancy through authorized channels, and support an objective investigation rather than rewriting the entries.

Apply it

An independent monitoring committee reviews accumulating results and recommends a protocol-defined safety change. Wait for authorized study instructions, prepare affected site workflows, and maintain blinding rather than asking for arm-specific findings to guide informal local changes.

Apply it

An initial report identifies a participant, reporting clinician and suspect product, and describes an unexpected, reasonably suspected drug reaction that was life-threatening when it occurred. The sponsor has enough information to initiate the seven-calendar-day pathway and seeks follow-up information for the report due within eight additional days. Missing laboratory records should not delay the initial qualifying report.

Apply it

A newly hired assistant has EDC access but no documented training or delegated screening role. Arrange the required qualification review, study training and authorization before assigning eligibility assessments or other participant-facing activities to the assistant.

Apply it

Laboratory alerts repeatedly remain unreviewed while the investigator is away. Escalate immediately, arrange appropriately qualified coverage and track documented medical review, then address the supervision process that allowed the backlog to develop at the site.

Apply it

An amendment changes sample processing from immediate freezing to timed centrifugation. Train the staff who collect and process samples, verify practical understanding, update instructions, and document readiness before collecting specimens under the revised procedure at the site.

Apply it

A clinic has 200 potentially relevant patients; 25% are expected to qualify and 40% of those to consent. The estimated enrollment is 20, before considering competing studies or follow-up capacity, so a promise of 60 needs revision.

Apply it

A site has experienced research staff but no monitored freezer needed for study specimens. Identify the gap during selection, establish a documented acquisition or qualified service plan, and verify readiness before affected trial activities begin.

Apply it

A central vendor repeatedly fails to deliver participant devices. Inform the investigator and responsible sponsor contact, document the impact, and use the agreed escalation pathway instead of assuming vendor involvement removes the need for site follow-up.

Apply it

The initiation meeting is complete, but the randomization system remains inaccessible and consent approval is outstanding. Track both conditions to resolution and withhold dependent enrollment activities until approvals and required operational access are established at the site.

Apply it

Central review identifies unusually frequent missing primary-outcome assessments at one site. Prepare relevant source records, investigate workflow causes and support targeted monitoring of outcome collection rather than assuming routine visit frequency alone provides adequate oversight.

Apply it

A monitor requests an entire identifiable clinic database by ordinary email. Arrange the approved secure review method and limit access to authorized trial records, escalating any uncertainty about consent or institutional access requirements before disclosure occurs.

Apply it

A monitoring letter lists an unresolved safety assessment and several filing errors. Escalate the safety assessment promptly, assign owners to all findings, document corrective evidence and track closure while considering whether repeated filing problems indicate a broader process weakness.

Apply it

Three samples miss processing deadlines because the courier cutoff precedes the clinic’s scheduled collection time. Correct affected records and assess impact, then redesign scheduling or transport; broad reminders to work faster would not address the identified mismatch.

Apply it

After revising consent version controls, review the next 15 consent encounters for correct approved versions and documented discussions. Compare findings with the predefined acceptance criterion and reopen the CAPA if the same failure recurs during that review.

Apply it

At close-out, one participant’s adverse event remains unresolved and several product returns await authorization. Document continuing follow-up responsibilities and complete authorized reconciliation and disposition instead of signing a blanket statement that all trial obligations have ended.

Apply it

The sponsor terminates a trial for a safety concern. Help the investigator contact participants, arrange appropriate medical follow-up, control affected product and document required communications while clarifying which assessments remain authorized and useful for participant safety.

Apply it

A site receives 120 kits, dispenses 45 and sends 10 unopened kits back to the sponsor, with no other movements. Usable inventory should be 65 kits; compare this with physical stock and investigate any discrepancy.

Apply it

The shipment quantity matches the manifest, but the temperature indicator shows a possible excursion. Record receipt, segregate the affected stock and request a documented suitability decision before releasing it for participant dispensing at the site.

Apply it

An overnight power failure exposes study stock to temperatures outside its specified range. Secure the stock against use, preserve the monitoring trace, identify affected lots and obtain the responsible team’s documented assessment before any further dispensing.

Apply it

A recall identifies two kit ranges, one already dispensed. Quarantine remaining affected kits, reconcile the records, notify the investigator and sponsor, and support participant-specific instructions rather than limiting the response to stock still at the site.

Apply it

A bottle count suggests perfect adherence, but the participant reports discarding missed tablets before returning it. Document the account accurately, assess implications with the investigator and provide nonjudgmental instruction rather than retaining the count-based estimate as confirmed exposure.

Apply it

A protocol sets a visit on day 28 with a plus-or-minus three-day window after randomization. A day-32 appointment lies outside that window; seek an in-window option or manage and document the actual departure transparently.

Apply it

An urgent laboratory alert arrives while the usual investigator is unavailable. Use the established qualified coverage pathway, document the alert and escalation, and track the resulting clinical instructions instead of waiting for the investigator’s next routine visit.

Apply it

Two tubes arrive with conflicting participant identifiers after a busy collection session. Segregate them, preserve collection records and follow the discrepancy process; do not relabel based solely on which participant staff remember seeing first that morning.

Apply it

A sample requires freezing within a specified interval, but a courier delay is discovered after processing. Record actual collection, processing and storage times, notify the responsible laboratory and study team, and obtain a documented decision about analysis suitability.

Apply it

A study scale fails its scheduled accuracy check. Remove it from trial use, arrange qualified correction and identify measurements since the last acceptable check for impact assessment before deciding whether any reassessment is needed for affected participants.

Apply it

A home-visit vendor repeatedly submits assessments without required timestamps. Document the pattern, notify responsible site and sponsor contacts, clarify contractual and protocol expectations, and track corrected processes and impact assessment rather than sending isolated reminders indefinitely.

Apply it

An amendment adds three lengthy assessments per participant, but the original budget covers none of the additional staff time. Flag the resource gap and coordinate revised arrangements while preserving required participant protection and authorized study procedures.

Apply it

Enrollment increases just as the next laboratory-kit shipment is delayed. Compare upcoming visits with usable kit quantities and expiry dates, escalate the projected shortage, and arrange an approved supply solution before participants arrive for affected scheduled assessments.

Apply it

The eCRF lists an assessment on Monday, while the signed source note records Tuesday. Check the underlying appointment and assessment evidence, determine the correct date, and make an attributable correction in the appropriate record with explanation.

Apply it

A coordinator discovers a transcription error two days after entry. Correct it through the authorized system function using the current date, preserve the previous value and record the reason rather than changing the timestamp to the visit date.

Apply it

An automated query flags an unusually high measurement that matches a verified source record. Confirm the observation and relevant context, obtain investigator review if clinically appropriate, and explain the value instead of lowering it to clear the query.

Apply it

A monitor confirms that the eCRF matches the source, then notices the assessment occurred before consent. Transcription verification is satisfactory, but broader source review has identified a conduct issue requiring investigation and appropriate escalation at the site.

Apply it

A key decision about a specimen procedure exists only in an employee’s personal mailbox. Preserve the authorized communication in the appropriate trial record system, identify the resulting instructions and ensure continued access when that employee leaves.

Apply it

A site plans to discard paper records after scanning. Establish certification through a dated verification signature or a validated copying process, confirm preservation of the original information and relevant metadata, and separately verify retention, access and destruction authorization before replacing originals.

Apply it

A blinded assessor receives a new system role that exposes treatment assignments. Stop unnecessary access, notify the responsible team, assess whether disclosure occurred and correct permissions while documenting the issue and any impact on trial blinding.

Apply it

A laboratory transfer imports values correctly but changes the displayed units incorrectly. Preserve the affected data and transfer evidence, escalate the mapping defect, assess impacted records and verify the corrected interface before relying on the transferred results.

Apply it

The safety system records an event as ongoing, while the eCRF gives a resolution date. Review follow-up evidence with the investigator, reconcile or explain the difference, and complete required approvals before treating the dataset as ready for lock.